Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship - Priority Announcement: Drug Safety and Effectiveness

McMaster University

$275,000.00

Improving Medication PRescribing for Ontario's Vulnerable Elderly High Cost Healthcare Users (IMPROVE-HCU)

EF 2016-17

Résumé
High cost healthcare users (HCUs) are a small group of patients that use a disproportionate healthcare resources compared to the average patient. In 2011, 5% of Ontarians used 65% ($19.8 billion) of total measurable public healthcare expenditures. Most HCUs are seniors with multiple chronic conditions taking multiple medications. With costs expected to double in 20 years, the current approach to HCUs has been deemed unsustainable by leading economists and there is an urgent need to design interventions to improve their health outcomes and costs. Our proposed research program seeks to better understand the impact of prescribing quality and drug use in senior HCUs. It is currently unknown whether HCUs are using optimal drugs and whether savings can be found through more cost-effective drug use. In Study 1, we will be using health administrative databases to investigate the current quality of prescribing and drug use in senior HCUs. We will be using the STOPP-START screening tool to look for potentially inappropriate prescribing that should have been stopped or started based on high quality scientific evidence. We will also explore the cost-savings if the government adopted a policy known as "reference-based pricing" for select high cost drugs with cheaper, equally effective alternatives. In Study 2, we will test the feasibility of conducting a large randomized trial to test the effectiveness of a new strategy to optimize drugs for hospitalized seniors HCUs to reduce their risk of death, re-hospitalization and healthcare costs. This project will demonstrate the impact of optimizing medications for Canada's high need, high cost seniors. It is the first of its kind internationally and it will help clinicians, hospitals and government develop new strategies to address the healthcare sustainability crisis. If only 10% of HCU expenses could be avoided or delayed, an additional $1.7 billion would be available in Ontario alone to fund better care for these seniors.
Programme
Fellowship - Priority Announcement: Drug Safety and Effectiveness
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
363843
Name
Lee Justin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Health Research Training B - HP
Projecttitle
Improving Medication PRescribing for Ontario's Vulnerable Elderly High Cost Healthcare Users (IMPROVE-HCU)
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$275,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Drug Safety and Effectiveness
Keyworddelim
Deprescribing; High Cost Healthcare User (Hcu); Polypharmacy; Prescribing Appropriateness; Prescribing Quality
Abstract
High cost healthcare users (HCUs) are a small group of patients that use a disproportionate healthcare resources compared to the average patient. In 2011, 5% of Ontarians used 65% ($19.8 billion) of total measurable public healthcare expenditures. Most HCUs are seniors with multiple chronic conditions taking multiple medications. With costs expected to double in 20 years, the current approach to HCUs has been deemed unsustainable by leading economists and there is an urgent need to design interventions to improve their health outcomes and costs. Our proposed research program seeks to better understand the impact of prescribing quality and drug use in senior HCUs. It is currently unknown whether HCUs are using optimal drugs and whether savings can be found through more cost-effective drug use. In Study 1, we will be using health administrative databases to investigate the current quality of prescribing and drug use in senior HCUs. We will be using the STOPP-START screening tool to look for potentially inappropriate prescribing that should have been stopped or started based on high quality scientific evidence. We will also explore the cost-savings if the government adopted a policy known as "reference-based pricing" for select high cost drugs with cheaper, equally effective alternatives. In Study 2, we will test the feasibility of conducting a large randomized trial to test the effectiveness of a new strategy to optimize drugs for hospitalized seniors HCUs to reduce their risk of death, re-hospitalization and healthcare costs. This project will demonstrate the impact of optimizing medications for Canada's high need, high cost seniors. It is the first of its kind internationally and it will help clinicians, hospitals and government develop new strategies to address the healthcare sustainability crisis. If only 10% of HCU expenses could be avoided or delayed, an additional $1.7 billion would be available in Ontario alone to fund better care for these seniors.
Competitiondate
201611
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Lee, Justin
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $275,000~ $0~